Comparative Pharmacology
Head-to-head clinical analysis: HUMALOG MIX 75 25 KWIKPEN versus NOVOLOG FLEXPEN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HUMALOG MIX 75 25 KWIKPEN versus NOVOLOG FLEXPEN.
HUMALOG MIX 75/25 KWIKPEN vs NOVOLOG FLEXPEN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Insulin lispro is a rapid-acting insulin analog that lowers blood glucose by promoting peripheral glucose uptake (especially in muscle and adipose tissue) and inhibiting hepatic glucose production. It binds to the insulin receptor, activating tyrosine kinase signaling pathways.
Insulin analog that lowers blood glucose by binding to insulin receptors, facilitating cellular uptake of glucose, and inhibiting hepatic glucose production.
Subcutaneous injection, individualized based on metabolic needs. Typical adult dose: 0.5-1.0 units/kg/day divided into preprandial doses. Administer within 15 minutes before a meal.
Subcutaneous injection; 0.5 to 1.0 unit/kg/day divided into doses at mealtimes; dose individualization based on metabolic needs and blood glucose monitoring.
None Documented
None Documented
4-6 minutes for insulin lispro (rapidly absorbed and cleared); terminal elimination half-life of insulin lispro is approximately 1 hour (reflecting dissociation from insulin receptors). Clinical context: the brief half-life allows for rapid dose adjustments and reduced risk of late hypoglycemia.
Terminal elimination half-life: 5-7 minutes (free insulin aspart in plasma); clinically, the prolonged action (up to 6 hours) reflects continued absorption from subcutaneous depot, not elimination half-life
Renal: 100% (metabolized to inactive metabolites; metabolites excreted via kidneys). Biliary/fecal: negligible.
Primarily renal (60-80% as unchanged drug via glomerular filtration and tubular reabsorption); biliary/fecal excretion minimal (<2%)
Category C
Category C
Insulin Analog
Insulin Analog